WO2003070083A3 - Endothelial precursor cells for enhancing and restoring vascular function - Google Patents

Endothelial precursor cells for enhancing and restoring vascular function Download PDF

Info

Publication number
WO2003070083A3
WO2003070083A3 PCT/US2003/004244 US0304244W WO03070083A3 WO 2003070083 A3 WO2003070083 A3 WO 2003070083A3 US 0304244 W US0304244 W US 0304244W WO 03070083 A3 WO03070083 A3 WO 03070083A3
Authority
WO
WIPO (PCT)
Prior art keywords
enhancing
precursor cells
vascular function
endothelial precursor
restoring vascular
Prior art date
Application number
PCT/US2003/004244
Other languages
French (fr)
Other versions
WO2003070083A2 (en
Inventor
Jay M Edelberg
Shahin Rafii
Mun K Hong
Robert P Lanza
Michael D West
Original Assignee
Cornell Res Foundation Inc
Jay M Edelberg
Shahin Rafii
Mun K Hong
Robert P Lanza
Michael D West
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/025175 external-priority patent/WO2003013570A1/en
Application filed by Cornell Res Foundation Inc, Jay M Edelberg, Shahin Rafii, Mun K Hong, Robert P Lanza, Michael D West filed Critical Cornell Res Foundation Inc
Priority to AU2003215189A priority Critical patent/AU2003215189A1/en
Publication of WO2003070083A2 publication Critical patent/WO2003070083A2/en
Publication of WO2003070083A3 publication Critical patent/WO2003070083A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/04—Cells produced using nuclear transfer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides methods of treating and preventing loss of tissue vascularization that can occur, for example, upon aging.
PCT/US2003/004244 2002-02-15 2003-02-13 Endothelial precursor cells for enhancing and restoring vascular function WO2003070083A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003215189A AU2003215189A1 (en) 2002-02-15 2003-02-13 Endothelial precursor cells for enhancing and restoring vascular function

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35732802P 2002-02-15 2002-02-15
US60/357,328 2002-02-15
USPCT/US02/25175 2002-08-08
PCT/US2002/025175 WO2003013570A1 (en) 2001-08-09 2002-08-08 Platelet-derived growth factor protection of cardiac myocardium

Publications (2)

Publication Number Publication Date
WO2003070083A2 WO2003070083A2 (en) 2003-08-28
WO2003070083A3 true WO2003070083A3 (en) 2004-04-08

Family

ID=27759854

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/004244 WO2003070083A2 (en) 2002-02-15 2003-02-13 Endothelial precursor cells for enhancing and restoring vascular function

Country Status (2)

Country Link
AU (1) AU2003215189A1 (en)
WO (1) WO2003070083A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1469064A1 (en) * 2003-04-15 2004-10-20 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Expression of proteins in endothelial cells derived from precursor cells from cord blood
EP4247408A1 (en) * 2020-11-20 2023-09-27 UNIVERSITÄTSmedizin der Johannes Gutenberg- Universität Mainz Inhibitors of the tissue factor-protease activated receptor 2 (tf-par2) signaling pathway for use in the treatment or prevention of heart failure (hf) and associated or resulting diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GILL M. ET AL.: "Vascular trauma induces rapid but transient mobilization of VEGFR2+ AC133+ endothelial precursor cells", CIRCULATION RESEARCH, vol. 88, 2 February 2001 (2001-02-02), pages 167 - 174, XP002217420 *

Also Published As

Publication number Publication date
AU2003215189A8 (en) 2003-09-09
WO2003070083A2 (en) 2003-08-28
AU2003215189A1 (en) 2003-09-09

Similar Documents

Publication Publication Date Title
WO2006002399A3 (en) Biodegradable implantable medical devices, methods and systems
WO2005011592A3 (en) Substituted indazole-o-glucosides
WO2003101397A3 (en) Tetravalent dengue vaccines
WO2005012243A3 (en) Substituted indole-o-glucosides
AU2002325835A1 (en) Treatment method, which promotes the removal of dirt, for the surfaces of textiles and non-textiles
WO2007070630A3 (en) Implantable devices for accelerated healing
WO2004021926A3 (en) Embolic protection filter assembly
WO2001019992A3 (en) FACTOR IX/FACTOR IXa ANTIBODIES AND ANTIBODY DERIVATIV ES
WO2001014424A3 (en) Human ctla-4 antibodies and their uses
WO2005110479A3 (en) Treatments for pancreatic cancer
WO2006023649A3 (en) Treatment of severe multiple sclerosis
WO2005045001A3 (en) Insulin-producing cells derived from stem cells
WO2001078702A3 (en) Methods and compositions for modulating alpha adrenergic receptor activity
WO2003088897A3 (en) Fab i inhibitors
WO2002076499A3 (en) Combination treatment of pancreatic cancer
EP1587574A4 (en) SELECTIVE 11b-HSD INHIBITORS AND METHODS FOR USE THEREOF
WO2001078703A3 (en) Methods and compositions for modulating alpha adrenergic receptor activity
WO2006060787A3 (en) Delaying or preventing onset of multiple sclerosis
AU2003222513A1 (en) Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure
WO2006013261A3 (en) Use of gingival fibroblasts for vascular cell therapy
WO2003010291A3 (en) Treatment of immune disorders and b cell disorders
WO2003053180A3 (en) Undergarments containing active substances
AU2003232115A1 (en) Methods and compositions for the treatment of graft failure
WO2004091436A3 (en) Methods and compositions for treating ocular disease
AU2003256483A8 (en) Methods of electrochemically treating semiconductor substrates, and methods of forming capacitor constructions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP